Copley Gets a New Life
Executive Summary
After a few volatile years, Copley Pharmaceutical has a new management team, which is gearing up the generics company for growth. Hoechst, which owns 51% of Copley, has said it wants to get out of the generics business and is letting the new management decide on an exit strategy. New CEO Daniel Korpolinski (previously head of CoCensys), believes that Copley's relationships with top national drug store chains remain strong and will help its revival.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.